Видео с ютуба Anti-Cd19 Antibodies

Anti-CD19 monoclonal antibodies for the treatment of DLBCL

Anti-CD19 Monoclonal Antibody Therapy in DLBCL

Anti-CD19 monoclonal antibodies for the treatment of DLBCL

Lenalidomide with CD19 antibodies in L-MIND

Mechanism of Action: T Cell Engagers Targeting CD19

Transplant Ineligibility: Anti-CD19 Combination Therapy

Bispecific CAR T-cell therapy: combining anti-CD19 and CD22 CAR T-cells

Out of specification anti-CD19 CAR T-cell products in aggressive B-cell lymphomas

Treatment of R/R DLBCL: CD19-Targeted Monoclonal Antibodies

Fully human anti-CD19 and CD22 bispecific tandem CAR-T

CIPO2015: Dual Targeting of CD19 & CD22 on B-ALL Using a Single Bispecific Chimeric Antigen Receptor

Exploring novel humanized anti-CD19 CAR-T cells as a strategy to minimize CRS and other toxicities

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy

New antibodies and antibody-drug conjugates for B-cell lymphoma

Dual-targeted anti-CD19/anti-CD20 CAR T-cells in R/R MCL: insights from a Phase I/II trial

CD19 CAR T-cells for adults

Anti-CD19 CAR T-cells for adults

ENABLE: third-generation anti-CD19 CAR for R/R NHL

Safety profile of anti-CD19 CAR T-cell therapy axicabtagene ciloleucel

Infusion of allogeneic anti-CD19 CAR T-cells is a promising approach after alloHSCT